| Autor: |
Manasi S Singh, Thomas M. Fishbein, Elizabeth Sindhi, Prabhakar K. Baliga, Jose Luis Almeda, Rakesh Sindhi, Stuart S. Kaufman, Pradeep Sethi, Shankar Subramaniam, George V. Mazariegos, Vinayak Rohan, Neha Atale, Geoffrey Bond, Ekong U, Brandon W. Higgs, Kavitha Mukund, Nada Yazigi, Chethan Ashokkumar, Monica M. Betancourt-Garcia, Ajai Khanna, Harmeet Dhani, Kyle Soltys, Sohail Rao, Satish N. Nadig, K. Khan, Shikhar Mehrotra, Mylarappa Ningappa, Alexander Kroemer, Brianna Spishock, Maggie Saunders |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
bioRxiv |
| DOI: |
10.1101/2021.05.03.442371 |
| Popis: |
Assessment of T-cell immunity to the COVID-19 coronavirus requires reliable assays and is of great interest, given the uncertain longevity of the antibody response. Some recent reports have used immunodominant spike (S) antigenic peptides and anti-CD28 co-stimulation in varying combinations to assess T-cell immunity to SARS-CoV-2. These assays may cause T-cell hyperstimulation and could overestimate antiviral immunity in chronically immunosuppressed transplant recipients, who are predisposed to infections and vaccination failures. Here, we evaluate CD154-expressing T-cells induced by unselected S antigenic peptides in 204 subjects-103 COVID-19 patients and 101 healthy unexposed subjects. Subjects included 72 transplanted and 130 non-transplanted subjects. S-reactive CD154+T-cells co-express and can thus substitute for IFNγ (n=3). Assay reproducibility in a variety of conditions was acceptable with coefficient of variation of 2-10.6%. S-reactive CD154+T-cell frequencies were a) higher in 42 healthy unexposed transplant recipients who were sampled pre-pandemic, compared with 59 healthy non-transplanted subjects (p=0.02), b) lower in Tr COVID-19 patients compared with healthy transplant patients (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
